| Literature DB >> 28756840 |
Ian R Baxendale1, Richard D Braatz2, Benjamin K Hodnett3, Klavs F Jensen2, Martin D Johnson4, Paul Sharratt5, Jon-Paul Sherlock6, Alastair J Florence7.
Abstract
This whitepaper highlights current challenges and opportunities associated with continuous synthesis, workup, and crystallization of active pharmaceutical ingredients (drug substances). We describe the technologies and requirements at each stage and emphasize the different considerations for developing continuous processes compared with batch. In addition to the specific sequence of operations required to deliver the necessary chemical and physical transformations for continuous drug substance manufacture, consideration is also given to how adoption of continuous technologies may impact different manufacturing stages in development from discovery, process development, through scale-up and into full scale production. The impact of continuous manufacture on drug substance quality and the associated challenges for control and for process safety are also emphasized. In addition to the technology and operational considerations necessary for the adoption of continuous manufacturing (CM), this whitepaper also addresses the cultural, as well as skills and training, challenges that will need to be met by support from organizations in order to accommodate the new work flows. Specific action items for industry leaders are.Keywords: PAT; continuous manufacturing; crystallization; drug substance; quality; safety; skills; synthetic methods
Year: 2016 PMID: 28756840 DOI: 10.1002/jps.24252
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534